|
1
|
Niiro H and Clark EA: Regulation of B-cell
fate by antigen-receptor signals. Nat Rev Immunol. 2:945–956. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bojarczuk K, Bobrowicz M, Dwojak M, Miazek
N, Zapala P, Bunes A, Siernicka M, Rozanska M and Winiarska M:
B-cell receptor signaling in the pathogenesis of lymphoid
malignancies. Blood Cells Mol Dis. 55:255–265. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mohamed AJ, Vargas L, Nore BF, Backesjo
CM, Christensson B and Smith CI: Nucleocytoplasmic shuttling of
Bruton's tyrosine kinase. J Biol Chem. 275:40614–40619. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hendriks RW, Yuvaraj S and Kil LP:
Targeting Bruton's tyrosine kinase in B cell malignancies. Nat Rev
Cancer. 14:219–232. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Honigberg LA, Smith AM, Sirisawad M,
Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, et
al: The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell
activation and is efficacious in models of autoimmune disease and
B-cell malignancy. Proc Natl Acad Sci USA. 107:13075–13080. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Small S: Ibrutinib approved for the
treatment of mantle cell lymphoma. Clin Adv Hematol Oncol.
11:8082013.
|
|
7
|
Dangi-Garimella S: FDA grants accelerated
approval for ibrutinib for CLL. Am J Manag Care.
20:E102014.PubMed/NCBI
|
|
8
|
Raedler LA: Imbruvica (Ibrutinib): First
drug approved for the treatment of patients with Waldenströms
macroglobulinemia. Am Health Drug Benefits. 9:(Spec Feature).
89–92. 2016.PubMed/NCBI
|
|
9
|
Packard TA and Cambier JC: B lymphocyte
antigen receptor signaling: Initiation, amplification, and
regulation. F1000Prime Rep. 5:402013. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rickert RC: New insights into pre-BCR and
BCR signalling with relevance to B cell malignancies. Nat Rev
Immunol. 13:578–591. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kaur V and Swami A: Ibrutinib in CLL: A
focus on adverse events, resistance, and novel approaches beyond
ibrutinib. Ann Hematol. 96:1175–1184. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Y, Zhang LL, Champlin RE and Wang ML:
Targeting Bruton's tyrosine kinase with ibrutinib in B-cell
malignancies. Clin Pharmacol Ther. 97:455–468. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vetrie D, Vorechovský I, Sideras P,
Holland J, Davies A, Flinter F, Hammarström L, Kinnon C, Levinsky
R, Bobrow M, et al: The gene involved in X-linked
agammaglobulinaemia is a member of the src family of
protein-tyrosine kinases. Nature. 361:226–233. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bruton OC: Agammaglobulinemia. Pediatrics.
9:722–728. 1952.PubMed/NCBI
|
|
15
|
Hagemann TL, Chen Y, Rosen FS and Kwan SP:
Genomic organization of the Btk gene and exon scanning for
mutations in patients with X-linked agammaglobulinemia. Hum Mol
Genet. 3:1743–1749. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheng S, Ma J, Guo A, Lu P, Leonard JP,
Coleman M, Liu M, Buggy JJ, Furman RR and Wang YL: BTK inhibition
targets in vivo CLL proliferation through its effects on B-cell
receptor signaling activity. Leukemia. 28:649–657. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Berglöf A, Hamasy A, Meinke S, Palma M,
Krstic A, Månsson R, Kimby E, Österborg A and Smith CI: Targets for
ibrutinib beyond B cell malignancies. Scand J Immunol. 82:208–217.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bradshaw JM: The Src, Syk, and Tec family
kinases: Distinct types of molecular switches. Cell Signal.
22:1175–1184. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pan Z, Scheerens H, Li SJ, Schultz BE,
Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC,
Grothaus PG, et al: Discovery of selective irreversible inhibitors
for Bruton's tyrosine kinase. ChemMedChem. 2:58–61. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kawakami Y, Kitaura J, Hata D, Yao L and
Kawakami T: Functions of Bruton's tyrosine kinase in mast and B
cells. J Leukoc Biol. 65:286–290. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Khare A, Viswanathan B, Gund R, Jain N,
Ravindran B, George A, Rath S and Bal V: Role of Bruton's tyrosine
kinase in macrophage apoptosis. Apoptosis. 16:334–346. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bao Y, Zheng J, Han C, Jin J, Han H, Liu
Y, Lau YL, Tu W and Cao X: Tyrosine kinase Btk is required for NK
cell activation. J Biol Chem. 287:23769–23778. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stiff A, Trikha P, Wesolowski R, Kendra K,
Hsu V, Uppati S, McMichael E, Duggan M, Campbell A, Keller K, et
al: Myeloid-derived suppressor cells express Bruton's tyrosine
kinase and can be depleted in tumor-bearing hosts by ibrutinib
treatment. Cancer Res. 76:2125–2136. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Satterthwaite AB, Li Z and Witte ON: Btk
function in B cell development and response. Semin Immunol.
10:309–316. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Küppers R: Mechanisms of B-cell lymphoma
pathogenesis. Nat Rev Cancer. 5:251–262. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Buggy JJ and Elias L: Bruton tyrosine
kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol.
31:119–132. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cinar M, Hamedani F, Mo Z, Cinar B, Amin
HM and Alkan S: Bruton tyrosine kinase is commonly overexpressed in
mantle cell lymphoma and its attenuation by Ibrutinib induces
apoptosis. Leuk Res. 37:1271–1277. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Goodman PA, Wood CM, Vassilev AO, Mao C
and Uckun FM: Defective expression of Bruton's tyrosine kinase in
acute lymphoblastic leukemia. Leuk Lymphoma. 44:1011–1018. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pal Singh S, Dammeijer F and Hendriks RW:
Role of Bruton's tyrosine kinase in B cells and malignancies. Mol
Cancer. 17:572018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Brown JR: Ibrutinib (PCI-32765), the first
BTK (Bruton's tyrosine kinase) inhibitor in clinical trials. Curr
Hematol Malig Rep. 8:1–6. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Singh J, Petter RC and Kluge AF: Targeted
covalent drugs of the kinase family. Curr Opin Chem Biol.
14:475–480. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Grabinski N and Ewald F: Ibrutinib
(ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and
cell viability of ErbB2-positive breast cancer cells. Invest New
Drugs. 32:1096–1104. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zucha MA, Wu AT, Lee WH, Wang LS, Lin WW,
Yuan CC and Yeh CT: Bruton's tyrosine kinase (Btk) inhibitor
ibrutinib suppresses stem-like traits in ovarian cancer.
Oncotarget. 6:13255–13268. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang JD, Chen XY, Ji KW and Tao F:
Targeting Btk with ibrutinib inhibit gastric carcinoma cells
growth. Am J Transl Res. 8:3003–3012. 2016.PubMed/NCBI
|
|
35
|
Gao W, Wang M, Wang L, Lu H, Wu S, Dai B,
Ou Z, Zhang L, Heymach JV, Gold KA, et al: Selective antitumor
activity of ibrutinib in EGFR-mutant non-small cell lung cancer
cells. J Natl Cancer Inst. 106:dju2042014.doi: 10.1093/jnci/dju204.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wei L, Su YK, Lin CM, Chao TY, Huang SP,
Huynh TT, Jan HJ, Whang-Peng J, Chiou JF, Wu AT, et al: Preclinical
investigation of ibrutinib, a Bruton's kinase tyrosine (Btk)
inhibitor, in suppressing glioma tumorigenesis and stem cell
phenotypes. Oncotarget. 7:69961–69975. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang J, Liu X, Hong Y, Wang S, Chen P, Gu
A, Guo X and Zhao P: Ibrutinib, a Bruton's tyrosine kinase
inhibitor, exhibits antitumoral activity and induces autophagy in
glioblastoma. J Exp Clin Cancer Res. 36:962017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rushworth SA, Pillinger G, Abdul-Aziz A,
Piddock R, Shafat MS, Murray MY, Zaitseva L, Lawes MJ, MacEwan DJ
and Bowles KM: Activity of Bruton's tyrosine-kinase inhibitor
ibrutinib in patients with CD117-positive acute myeloid leukaemia:
A mechanistic study using patient-derived blast cells. Lancet
Haematol. 2:e204–e211. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim E, Hurtz C, Koehrer S, Wang Z,
Balasubramanian S, Chang BY, Müschen M, Davis RE and Burger JA:
Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic
leukemia progression by targeting BTK and BLK. Blood.
129:1155–1165. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Deeks ED: Ibrutinib: A Review in chronic
lymphocytic leukaemia. Drugs. 77:225–236. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
de Zwart L, Snoeys J, De Jong J,
Sukbuntherng J, Mannaert E and Monshouwer M: Ibrutinib dosing
strategies based on interaction potential of CYP3A4 perpetrators
using physiologically based pharmacokinetic modeling. Clin
Pharmacol Ther. 100:548–557. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Finnes HD, Chaffee KG, Call TG, Ding W,
Kenderian SS, Bowen DA, Conte M, McCullough KB, Merten JA, Bartoo
GT, et al: Pharmacovigilance during ibrutinib therapy for chronic
lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in
routine clinical practice. Leuk Lymphoma. 58:1376–1383. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
FDA U: Imbruvica (ibrutinib) capsules: US
prescribing information. http://www.fda.gov.2016
|
|
44
|
Ltd J-C: Imbruvica 140 mg hard capsules.
https://www.medicines.org.uk/emc/medicine/293832018
|
|
45
|
Herman SEM, Gordon AL, Hertlein E,
Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy
JJ, et al: Bruton tyrosine kinase represents a promising
therapeutic target for treatment of chronic lymphocytic leukemia
and is effectively targeted by PCI-32765. Blood. 117:6287–6296.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Woyach JA, Bojnik E, Ruppert AS,
Stefanovski MR, Goettl VM, Smucker KA, Smith LL, Dubovsky JA, Towns
WH, MacMurray J, et al: Bruton's tyrosine kinase (BTK) function is
important to the development and expansion of chronic lymphocytic
leukemia (CLL). Blood. 123:1207–1213. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Herman SE, Sun X, McAuley EM, Hsieh MM,
Pittaluga S, Raffeld M, Liu D, Keyvanfar K, Chapman CM, Chen J, et
al: Modeling tumor-host interactions of chronic lymphocytic
leukemia in xenografted mice to study tumor biology and evaluate
targeted therapy. Leukemia. 27:2311–2321. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
OBrien S, Furman RR, Coutre SE, Sharman
JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG,
et al: Ibrutinib as initial therapy for elderly patients with
chronic lymphocytic leukaemia or small lymphocytic lymphoma: An
open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 15:48–58.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Burger JA, Tedeschi A, Barr PM, Robak T,
Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, et al
RESONATE-2 Investigators, : Ibrutinib as initial yherapy for
patients with chronic lymphocytic leukemia. N Engl J Med.
373:2425–2437. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shanafelt TD, Wang V, Kay NE, Hanson CA,
OBrien SM, Barrientos JC, Erba HP, Stone RM, Litzow MR and Tallman
MS: A Randomized phase III study of ibrutinib (PCI-32765)-based
therapy vs. standard fludarabine, cyclophosphamide, and rituximab
(FCR) chemoimmunotherapy in untreated younger patients with chronic
lymphocytic leukemia (CLL): A trial of the ECOG-ACRIN Cancer
Research Group (E1912). Blood. 132:LBA–4-LBA-4. 2018. View Article : Google Scholar
|
|
51
|
Woyach JA, Ruppert AS, Heerema NA, Zhao W,
Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, et
al: Ibrutinib regimens versus chemoimmunotherapy in older patients
with untreated CLL. N Engl J Med. 379:2517–2528. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Moreno C, Greil R, Demirkan F, Tedeschi A,
Anz B, Larratt L, Simkovic M, Samoilova O, Novak J, Ben-Yehuda D,
et al: Ibrutinib plus obinutuzumab versus chlorambucil plus
obinutuzumab in first-line treatment of chronic lymphocytic
leukaemia (iLLUMINATE): A multicentre, randomised, open-label,
phase 3 trial. Lancet Oncol. 20:43–56. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Advani RH, Buggy JJ, Sharman JP, Smith SM,
Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, et
al: Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has
significant activity in patients with relapsed/refractory B-cell
malignancies. J Clin Oncol. 31:88–94. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Byrd JC, Furman RR, Coutre SE, Flinn IW,
Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, et
al: Targeting BTK with ibrutinib in relapsed chronic lymphocytic
leukemia. N Engl J Med. 369:32–42. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Byrd JC, Brown JR, OBrien S, Barrientos
JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, et
al RESONATE Investigators, : Ibrutinib versus ofatumumab in
previously treated chronic lymphoid leukemia. N Engl J Med.
371:213–223. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Byrd JC, Furman RR, Coutre SE, Burger JA,
Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, et al:
Three-year follow-up of treatment-naïve and previously treated
patients with CLL and SLL receiving single-agent ibrutinib. Blood.
125:2497–2506. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Coutré SE, Furman RR, Flinn IW, Burger JA,
Blum K, Sharman J, Jones J, Wierda W, Zhao W, Heerema NA, et al:
Extended treatment with single-agent ibrutinib at the 420 mg dose
leads to durable responses in chronic lymphocytic leukemia/small
lymphocytic lymphoma. Clin Cancer Res. 23:1149–1155. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
OBrien S, Furman RR, Coutre S, Flinn IW,
Burger JA, Blum K, Sharman J, Wierda W, Jones J, Zhao W, et al:
Single-agent ibrutinib in treatment-naïve and relapsed/refractory
chronic lymphocytic leukemia: A 5-year experience. Blood.
131:1910–1919. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Farooqui MZ, Valdez J, Martyr S, Aue G,
Saba N, Niemann CU, Herman SE, Tian X, Marti G, Soto S, et al:
Ibrutinib for previously untreated and relapsed or refractory
chronic lymphocytic leukaemia with TP53 aberrations: A phase 2,
single-arm trial. Lancet Oncol. 16:169–176. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ahn IE, Farooqui MZH, Tian X, Valdez J,
Sun C, Soto S, Lotter J, Housel S, Stetler-Stevenson M, Yuan CM, et
al: Depth and durability of response to ibrutinib in CLL: 5-year
follow-up of a phase 2 study. Blood. 131:2357–2366. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
OBrien S, Jones JA, Coutre SE, Mato AR,
Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, et
al: Ibrutinib for patients with relapsed or refractory chronic
lymphocytic leukaemia with 17p deletion (RESONATE-17): A phase 2,
open-label, multicentre study. Lancet Oncol. 17:1409–1418. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Jones J, Mato A, Coutre S, Byrd JC, Furman
RR, Hillmen P, Osterborg A, Tam C, Stilgenbauer S, Wierda WG, et
al: Evaluation of 230 patients with relapsed/refractory deletion
17p chronic lymphocytic leukaemia treated with ibrutinib from 3
clinical trials. Br J Haematol. 182:504–512. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Winqvist M, Asklid A, Andersson PO,
Karlsson K, Karlsson C, Lauri B, Lundin J, Mattsson M, Norin S,
Sandstedt A, et al: Real-world results of ibrutinib in patients
with relapsed or refractory chronic lymphocytic leukemia: Data from
95 consecutive patients treated in a compassionate use program. A
study from the Swedish Chronic Lymphocytic Leukemia Group.
Haematologica. 101:1573–1580. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Mato AR, Nabhan C, Barr PM, Ujjani CS,
Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, et
al: Outcomes of CLL patients treated with sequential kinase
inhibitor therapy: A real world experience. Blood. 128:2199–2205.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Ysebaert L, Aurran-Schleinitz T, Dartigeas
C, Dilhuydy MS, Feugier P, Michallet AS, Tournilhac O, Dupuis J,
Sinet P, Albrecht C, et al: Real-world results of ibrutinib in
relapsed/refractory CLL in France: Early results on a large series
of 428 patients. Am J Hematol. 92:E166–E168. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Mato AR, Hill BT, Lamanna N, Barr PM,
Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS,
et al: Optimal sequencing of ibrutinib, idelalisib, and venetoclax
in chronic lymphocytic leukemia: Results from a multicenter study
of 683 patients. Ann Oncol. 28:1050–1056. 2017.PubMed/NCBI
|
|
67
|
Hillmen P, Diels J, Healy N, Iraqi W,
Aschan J and Wildgust M: Ibrutinib for chronic lymphocytic
leukemia: International experience from a named patient program.
Haematologica. 103:e204–e206. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
UK CLL Forum, . Ibrutinib for
relapsed/refractory chronic lymphocytic leukemia: A UK and Ireland
analysis of outcomes in 315 patients. Haematologica. 101:1563–1572.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Barr PM, Brown JR, Hillmen P, OBrien S,
Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman
RR, et al: Impact of ibrutinib dose adherence on therapeutic
efficacy in patients with previously treated CLL/SLL. Blood.
129:2612–2615. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Da Roit F, Engelberts PJ, Taylor RP, Breij
EC, Gritti G, Rambaldi A, Introna M, Parren PW, Beurskens FJ and
Golay J: Ibrutinib interferes with the cell-mediated anti-tumor
activities of therapeutic CD20 antibodies: Implications for
combination therapy. Haematologica. 100:77–86. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Hing ZA, Mantel R, Beckwith KA, Guinn D,
Williams E, Smith LL, Williams K, Johnson AJ, Lehman AM, Byrd JC,
et al: Selinexor is effective in acquired resistance to ibrutinib
and synergizes with ibrutinib in chronic lymphocytic leukemia.
Blood. 125:3128–3132. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Younes A, Thieblemont C, Morschhauser F,
Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J,
Bandyopadhyay N, et al: Combination of ibrutinib with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)
for treatment-naive patients with CD20-positive B-cell non-Hodgkin
lymphoma: A non-randomised, phase 1b study. Lancet Oncol.
15:1019–1026. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Burger JA, Keating MJ, Wierda WG, Hartmann
E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli
A, Cardenas-Turanzas M, et al: Safety and activity of ibrutinib
plus rituximab for patients with high-risk chronic lymphocytic
leukaemia: A single-arm, phase 2 study. Lancet Oncol. 15:1090–1099.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Jaglowski SM, Jones JA, Nagar V, Flynn JM,
Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker
K, et al: Safety and activity of BTK inhibitor ibrutinib combined
with ofatumumab in chronic lymphocytic leukemia: A phase 1b/2
study. Blood. 126:842–850. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Maddocks K, Christian B, Jaglowski S,
Flynn J, Jones JA, Porcu P, Wei L, Jenkins C, Lozanski G, Byrd JC,
et al: A phase 1/1b study of rituximab, bendamustine, and ibrutinib
in patients with untreated and relapsed/refractory non-Hodgkin
lymphoma. Blood. 125:242–248. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Sharman JP, Farber CM, Mahadevan D,
Schreeder MT, Brooks HD, Kolibaba KS, Fanning S, Klein L, Greenwald
DR, Sportelli P, et al: Ublituximab (TG-1101), a novel
glycoengineered anti-CD20 antibody, in combination with ibrutinib
is safe and highly active in patients with relapsed and/or
refractory chronic lymphocytic leukaemia: Results of a phase 2
trial. Br J Haematol. 176:412–420. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Cervantes-Gomez F, Lamothe B, Woyach JA,
Wierda WG, Keating MJ, Balakrishnan K and Gandhi V: Pharmacological
and protein profiling suggests venetoclax (ABT-199) as optimal
partner with ibrutinib in chronic lymphocytic leukemia. Clin Cancer
Res. 21:3705–3715. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Brown JR, Barrientos JC, Barr PM, Flinn
IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, et
al: The Bruton tyrosine kinase inhibitor ibrutinib with
chemoimmunotherapy in patients with chronic lymphocytic leukemia.
Blood. 125:2915–2922. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Chanan-Khan A, Cramer P, Demirkan F,
Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J,
Bartlett NL, et al HELIOS investigators, : Ibrutinib combined with
bendamustine and rituximab compared with placebo, bendamustine, and
rituximab for previously treated chronic lymphocytic leukaemia or
small lymphocytic lymphoma (HELIOS): A randomised, double-blind,
phase 3 study. Lancet Oncol. 17:200–211. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Nastoupil L, Lunning MA, Vose JM,
Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda
WG, OBrien S, et al: Chemo-free triplet combination of TGR-1202,
ublituximab and ibrutinib is well tolerated and highly active in
patients with advanced CLL and NHL. Hematol Oncol. 35:112–113.
2017. View Article : Google Scholar
|
|
81
|
Ujjani C, Wang H, Skarbnik A, Trivedi N,
Ramzi P, Khan N and Cheson BD: A phase 1 study of lenalidomide and
ibrutinib in combination with rituximab in relapsed and refractory
CLL. Blood Adv. 2:762–768. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Hershkovitz-Rokah O, Pulver D, Lenz G and
Shpilberg O: Ibrutinib resistance in mantle cell lymphoma:
Clinical, molecular and treatment aspects. Br J Haematol.
181:306–319. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Furman RR, Cheng S, Lu P, Setty M, Perez
AR, Guo A, Racchumi J, Xu G, Wu H, Ma J, et al: Ibrutinib
resistance in chronic lymphocytic leukemia. N Engl J Med.
370:2352–2354. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Woyach JA, Ruppert AS, Guinn D, Lehman A,
Blachly JS, Lozanski A, Heerema NA, Zhao W, Coleman J, Jones D, et
al: BTKC481S-mediated resistance to ibrutinib in chronic
lymphocytic leukemia. J Clin Oncol. 35:1437–1443. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ahn IE, Underbayev C, Albitar A, Herman
SE, Tian X, Maric I, Arthur DC, Wake L, Pittaluga S, Yuan CM, et
al: Clonal evolution leading to ibrutinib resistance in chronic
lymphocytic leukemia. Blood. 129:1469–1479. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Ahn IE, Tian X, Albitar M, Herman SEM,
Cook EM, Soto S, Ma W, Ipe D, Tsao LC, Cheng M, et al: Validation
of clinical prognostic models and integration of genetic biomarkers
of drug resistance in CLL patients treated with ibrutinib. Blood.
132:186. 2018. View Article : Google Scholar
|
|
87
|
Quinquenel A, Fornecker LM, Letestu R,
Ysebaert L, Fleury C, Lazarian G, Dilhuydy MS, Nollet D, Guieze R,
Feugier P, et al: High prevalence of BTK mutations on ibrutinib
therapy after 3 years of treatment in a real-life cohort of CLL
patients: A study from the French Innovative Leukemia Organization
(FILO) Group. Blood. 132:584. 2018. View Article : Google Scholar
|
|
88
|
Boissard F, Fournié JJ, Quillet-Mary A,
Ysebaert L and Poupot M: Nurse-like cells mediate ibrutinib
resistance in chronic lymphocytic leukemia patients. Blood Cancer
J. 5:e3552015. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Borge M, Belén Almejún M, Podaza E, Colado
A, Fernández Grecco H, Cabrejo M, Bezares RF, Giordano M and
Gamberale R: Ibrutinib impairs the phagocytosis of rituximab-coated
leukemic cells from chronic lymphocytic leukemia patients by human
macrophages. Haematologica. 100:e140–e142. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman
SE, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R,
et al: Ibrutinib antagonizes rituximab-dependent NK cell-mediated
cytotoxicity. Blood. 123:1957–1960. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Jacobson C, Kopp N, Layer JV, Redd RA,
Tschuri S, Haebe S, van Bodegom D, Bird L, Christie AL,
Christodoulou A, et al: HSP90 inhibition overcomes ibrutinib
resistance in mantle cell lymphoma. Blood. 128:2517–2526. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Srour SA, Lee HJ, Nomie K, Ye H, Chen W,
Oriabure O, Romaguera J and Wang ML: Novel chemotherapy-free
combination regimen for ibrutinib-resistant mantle cell lymphoma.
Br J Haematol. 181:561–564. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Brown JR, Moslehi J, OBrien S, Ghia P,
Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ,
et al: Characterization of atrial fibrillation adverse events
reported in ibrutinib randomized controlled registration trials.
Haematologica. 102:1796–1805. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Gustine JN, Meid K, Dubeau TE, Treon SP
and Castillo JJ: Atrial fibrillation associated with ibrutinib in
Waldenström macroglobulinemia. Am J Hematol. 91:E312–E313. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Farooqui M, Valdez J, Soto S, Bray A, Tian
X and Wiestner A: Atrial fibrillation in CLL/SLL patients on
ibrutinib. Blood. 126:2933. 2015. View Article : Google Scholar
|
|
96
|
Leong DP, Caron F, Hillis C, Duan A,
Healey JS, Fraser G and Siegal D: The risk of atrial fibrillation
with ibrutinib use: A systematic review and meta-analysis. Blood.
128:138–140. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
McMullen JR, Boey EJ, Ooi JY, Seymour JF,
Keating MJ and Tam CS: Ibrutinib increases the risk of atrial
fibrillation, potentially through inhibition of cardiac PI3K-Akt
signaling. Blood. 124:3829–3830. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Thompson PA, Lévy V, Tam CS, Al Nawakil C,
Goudot FX, Quinquenel A, Ysebaert L, Michallet AS, Dilhuydy MS, Van
Den Neste E, et al: Atrial fibrillation in CLL patients treated
with ibrutinib. An international retrospective study. Br J
Haematol. 175:462–466. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Lambert Kuhn E, Levêque D, Lioure B,
Gourieux B and Bilbault P: Adverse event potentially due to an
interaction between ibrutinib and verapamil: A case report. J Clin
Pharm Ther. 41:104–105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Mulligan SP, Ward CM, Whalley D and Hilmer
SN: Atrial fibrillation, anticoagulant stroke prophylaxis and
bleeding risk with ibrutinib therapy for chronic lymphocytic
leukaemia and lymphoproliferative disorders. Br J Haematol.
175:359–364. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Wang ML, Blum KA, Martin P, Goy A, Auer R,
Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, et al:
Long-term follow-up of MCL patients treated with single-agent
ibrutinib: Updated safety and efficacy results. Blood. 126:739–745.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Vrontikis A, Carey J, Gilreath JA, Halwani
A, Stephens DM and Sweetenham JW: Proposed algorithm for managing
ibrutinib-related atrial fibrillation. Oncology (Williston Park).
30:970–974, 980-971, C973. 2016.PubMed/NCBI
|
|
103
|
Thorp BC and Badoux X: Atrial fibrillation
as a complication of ibrutinib therapy: Clinical features and
challenges of management. Leuk Lymphoma. 59:311–320. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
de Weerdt I, Koopmans SM, Kater AP and van
Gelder M: Incidence and management of toxicity associated with
ibrutinib and idelalisib: A practical approach. Haematologica.
102:1629–1639. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Jones JA, Hillmen P, Coutre S, Tam C,
Furman RR, Barr PM, Schuster SJ, Kipps TJ, Flinn IW, Jaeger U, et
al: Use of anticoagulants and antiplatelet in patients with chronic
lymphocytic leukaemia treated with single-agent ibrutinib. Br J
Haematol. 178:286–291. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Gribben JG, Bosch F, Cymbalista F, Geisler
CH, Ghia P, Hillmen P, Moreno C and Stilgenbauer S: Optimising
outcomes for patients with chronic lymphocytic leukaemia on
ibrutinib therapy: European recommendations for clinical practice.
Br J Haematol. 180:666–679. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Levade M, David E, Garcia C, Laurent PA,
Cadot S, Michallet AS, Bordet JC, Tam C, Sié P, Ysebaert L, et al:
Ibrutinib treatment affects collagen and von Willebrand
factor-dependent platelet functions. Blood. 124:3991–3995. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Lipsky AH, Farooqui MZ, Tian X, Martyr S,
Cullinane AM, Nghiem K, Sun C, Valdez J, Niemann CU, Herman SE, et
al: Incidence and risk factors of bleeding-related adverse events
in patients with chronic lymphocytic leukemia treated with
ibrutinib. Haematologica. 100:1571–1578. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Kamel S, Horton L, Ysebaert L, Levade M,
Burbury K, Tan S, Cole-Sinclair M, Reynolds J, Filshie R, Schischka
S, et al: Ibrutinib inhibits collagen-mediated but not ADP-mediated
platelet aggregation. Leukemia. 29:783–787. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Dreyling M, Jurczak W, Jerkeman M, Silva
RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C,
Witzens-Harig M, et al: Ibrutinib versus temsirolimus in patients
with relapsed or refractory mantle-cell lymphoma: An international,
randomised, open-label, phase 3 study. Lancet. 387:770–778. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Yun S, Vincelette ND, Acharya U and
Abraham I: Risk of atrial fibrillation and bleeding diathesis
associated with ibrutinib treatment: A systematic review and pooled
analysis of four randomized controlled trials. Clin Lymphoma
Myeloma Leuk. 17:31–37.e13. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Treon SP, Tripsas CK, Meid K, Warren D,
Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, et al:
Ibrutinib in previously treated Waldenströms macroglobulinemia. N
Engl J Med. 372:1430–1440. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Serebruany VL, Malinin AI, Ferguson JJ,
Vahabi J, Atar D and Hennekens CH: Bleeding risks of combination
vs. single antiplatelet therapy: a meta-analysis of 18 randomized
trials comprising 129314 patients. Fundam Clin Pharmacol.
22:315–321. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Shatzel JJ, Olson SR, Tao DL, McCarty OJT,
Danilov AV and DeLoughery TG: Ibrutinib-associated bleeding:
Pathogenesis, management and risk reduction strategies. J Thromb
Haemost. 15:835–847. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Dubovsky JA, Beckwith KA, Natarajan G,
Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY,
Larkin KM, et al: Ibrutinib is an irreversible molecular inhibitor
of ITK driving a Th1-selective pressure in T lymphocytes. Blood.
122:2539–2549. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Ghosh S, Bienemann K, Boztug K and
Borkhardt A: Interleukin-2-inducible T-cell kinase (ITK) deficiency
- clinical and molecular aspects. J Clin Immunol. 34:892–899. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Kreiniz N, Bejar J, Polliack A and Tadmor
T: Severe pneumonia associated with ibrutinib monotherapy for CLL
and lymphoma. Hematol Oncol. 2017.PubMed/NCBI
|
|
118
|
Issa N, Arbona-Haddad E, Nevett-Fernandez
A, Prestes D, Liakos A, Woolley A, Hammond S, Brown J, Baden L and
Marty F: Opportunistic infections (OIs) in patients with
hematologic malignancies (HM) treated with Bruton's tyrosine kinase
(BTK) and phosphoinositide 3 kinase (PI3K) inhibitors: An 8-year
retrospective cohort study. Open Forum Infect Dis. 4
(Suppl_1):S6992017. View Article : Google Scholar :
|
|
119
|
Chan TS, Au-Yeung R, Chim CS, Wong SC and
Kwong YL: Disseminated fusarium infection after ibrutinib therapy
in chronic lymphocytic leukaemia. Ann Hematol. 96:871–872. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Ahn IE, Jerussi T, Farooqui M, Tian X,
Wiestner A and Gea-Banacloche J: Atypical Pneumocystis
jirovecii pneumonia in previously untreated patients with CLL
on single-agent ibrutinib. Blood. 128:1940–1943. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Lionakis MS, Dunleavy K, Roschewski M,
Widemann BC, Butman JA, Schmitz R, Yang Y, Cole DE, Melani C,
Higham CS, et al: Inhibition of B cell receptor signaling by
ibrutinib in orimary CNS lymphoma. Cancer Cell. 31:833–843.e835.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Diamantopoulos PT, Psichogiou M,
Pantazatou A, Zervakis K, Rougala N, Giannakopoulou N, Daikos G and
Viniou NA: Staphylococcus aureus meningitis in a patient
with mantle cell lymphoma under treatment with ibrutinib. Ann
Hematol. 96:1049–1050. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Tillman BF, Pauff JM, Satyanarayana G,
Talbott M and Warner JL: Systematic review of infectious events
with the Bruton tyrosine kinase inhibitor ibrutinib in the
treatment of hematologic malignancies. Eur J Haematol. 2017.
|
|
124
|
Varughese T, Taur Y, Cohen N, Palomba ML,
Seo SK, Hohl TM and Redelman-Sidi G: Serious infections in patients
receiving ibrutinib for treatment of lymphoid cancer. Clin Infect
Dis. 67:687–692. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Ghez D, Calleja A, Protin C, Baron M,
Ledoux MP, Damaj G, Dupont M, Dreyfus B, Ferrant E, Herbaux C, et
al French Innovative Leukemia Organization (FILO) CLL group, :
Early-onset invasive aspergillosis and other fungal infections in
patients treated with ibrutinib. Blood. 131:1955–1959. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Wang SY, Ebert T, Jaekel N, Schubert S,
Niederwieser D and Al-Ali HK: Miliary tuberculosis after initiation
of ibrutinib in chronic lymphocytic leukemia. Ann Hematol.
94:1419–1420. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Sun C, Tian X, Lee YS, Gunti S, Lipsky A,
Herman SE, Salem D, Stetler-Stevenson M, Yuan C, Kardava L, et al:
Partial reconstitution of humoral immunity and fewer infections in
patients with chronic lymphocytic leukemia treated with ibrutinib.
Blood. 126:2213–2219. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Yin Q, Sivina M, Robins H, Yusko E,
Vignali M, OBrien S, Keating MJ, Ferrajoli A, Estrov Z, Jain N, et
al: Ibrutinib therapy Increases T cell repertoire diversity in
patients with chronic lymphocytic leukemia. J Immunol.
198:1740–1747. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Yeo W, Chan TC, Leung NW, Lam WY, Mo FK,
Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, et al: Hepatitis B virus
reactivation in lymphoma patients with prior resolved hepatitis B
undergoing anticancer therapy with or without rituximab. J Clin
Oncol. 27:605–611. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Yeo W and Johnson PJ: Diagnosis,
prevention and management of hepatitis B virus reactivation during
anticancer therapy. Hepatology. 43:209–220. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
de Jésus Ngoma P, Kabamba B, Dahlqvist G,
Sempoux C, Lanthier N, Shindano T, Van Den Neste E and Horsmans Y:
Occult HBV reactivation induced by ibrutinib treatment: A case
report. Acta Gastroenterol Belg. 78:424–426. 2015.PubMed/NCBI
|
|
132
|
Herishanu Y, Katchman H and Polliack A:
Severe hepatitis B virus reactivation related to ibrutinib
monotherapy. Ann Hematol. 96:689–690. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Tedeschi A, Frustaci AM, Mazzucchelli M,
Cairoli R and Montillo M: Is HBV prophylaxis required during CLL
treatment with ibrutinib? Leuk Lymphoma. 58:2966–2968. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Wang ML, Rule S, Martin P, Goy A, Auer R,
Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, et al:
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell
lymphoma. N Engl J Med. 369:507–516. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Ujjani CS, Jung SH, Pitcher B, Martin P,
Park SI, Blum KA, Smith SM, Czuczman M, Davids MS, Levine E, et al:
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in
previously untreated follicular lymphoma: Alliance A051103. Blood.
128:2510–2516. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Mannis G, Wu D, Dea T, Mauro T and Hsu G:
Ibrutinib rash in a patient with 17p del chronic lymphocytic
leukemia. Am J Hematol. 90:1792015. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Jensen AB, Stausbøl-Grøn B, Riber-Hansen R
and dAmore F: Ibrutinib-associated skin toxicity: A case of
maculopapular rash in a 79-year old Caucasian male patient with
relapsed Waldenstroms macroglobulinemia and review of the
literature. Dermatol Rep. 9:69762017. View Article : Google Scholar
|
|
138
|
Iberri DJ, Kwong BY, Stevens LA, Coutre
SE, Kim J, Sabile JM and Advani RH: Ibrutinib-associated rash: A
single-centre experience of clinicopathological features and
management. Br J Haematol. 2016.PubMed/NCBI
|
|
139
|
Neffendorf JE, Gout I and Hildebrand GD:
Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med.
369:1277–1279. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Wallace N, Wong E, Cooper D and Chao H: A
case of new-onset cardiomyopathy and ventricular tachycardia in a
patient receiving ibrutinib for relapsed mantle cell lymphoma. Clin
Case Rep. 4:1120–1121. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Lutz M, Schulze AB, Rebber E, Wiebe S,
Zoubi T, Grauer OM, Keßler T, Kerkhoff A, Lenz G and Berdel WE:
Progressive multifocal leukoencephalopathy after ibrutinib therapy
for chronic lymphocytic leukemia. Cancer Res Treat. 49:548–552.
2017. View Article : Google Scholar : PubMed/NCBI
|
